Refining the Galleria mellonella Model by Using Stress Marker Genes to Assess Clostridioides difficile Infection and Recuperation during Phage Therapy
- PMID: 32867060
- PMCID: PMC7564439
- DOI: 10.3390/microorganisms8091306
Refining the Galleria mellonella Model by Using Stress Marker Genes to Assess Clostridioides difficile Infection and Recuperation during Phage Therapy
Abstract
The Galleria mellonella is an effective model for probing Clostridioides difficile interactions with phages. Despite valuable insights from this model, the larvae are not easily amenable to assessing detailed clinical responses to either bacteria or phages. Here, larval survival, colonisation and toxin levels were compared to expression profiles of 17 G. mellonella stress genes to monitor Clostridiodes difficile infection (CDI), and recuperation during phage therapy. The larvae were infected with a ribotype 014/020 isolate and treated with an optimised phage cocktail. Larvae treated prophylactically with phages and the phage-control larval group were protected, showing the highest survival, and low C. difficile colonisation and toxin rates, compared to co-infection, remedial and bacterial-control larval groups. Expression of growth (9) and reproduction (2) genes were enhanced within prophylaxis and phage-control larval groups compared to the co-infection, remedial and bacterial control groups. In contrast, expression of infection (2), humoral (1) and cellular (3) immunity genes declined in the prophylactic and phage-control groups but increased in the co-infection, remedial and bacterial control larvae. The molecular markers augment the survival, colonisation and toxin data and allow detailed monitoring of CDI and recovery. This data support the use of stress marker genes as tools to analyse clinical symptoms in this model.
Keywords: Clostridiodes difficile infection; Clostridioides difficile; Clostridium difficile; Galleria mellonella; bacteriophage therapy; qPCR.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Diversity, Dynamics and Therapeutic Application of Clostridioides difficile Bacteriophages.Viruses. 2022 Dec 12;14(12):2772. doi: 10.3390/v14122772. Viruses. 2022. PMID: 36560776 Free PMC article. Review.
-
Impact of Phage CDHS-1 on the Transcription, Physiology and Pathogenicity of a Clostridioides difficile Ribotype 027 Strain, R20291.Viruses. 2021 Nov 11;13(11):2262. doi: 10.3390/v13112262. Viruses. 2021. PMID: 34835068 Free PMC article.
-
'Get in Early'; Biofilm and Wax Moth (Galleria mellonella) Models Reveal New Insights into the Therapeutic Potential of Clostridium difficile Bacteriophages.Front Microbiol. 2016 Aug 31;7:1383. doi: 10.3389/fmicb.2016.01383. eCollection 2016. Front Microbiol. 2016. PMID: 27630633 Free PMC article.
-
A Novel Bacteriophage with Broad Host Range against Clostridioides difficile Ribotype 078 Supports SlpA as the Likely Phage Receptor.Microbiol Spectr. 2022 Feb 23;10(1):e0229521. doi: 10.1128/spectrum.02295-21. Epub 2022 Feb 2. Microbiol Spectr. 2022. PMID: 35107319 Free PMC article.
-
Clostridioides difficile phage biology and application.FEMS Microbiol Rev. 2021 Sep 8;45(5):fuab012. doi: 10.1093/femsre/fuab012. FEMS Microbiol Rev. 2021. PMID: 33580957 Free PMC article. Review.
Cited by
-
The long and sinuous road to phage-based therapy of Clostridioides difficile infections.Front Med (Lausanne). 2023 Aug 23;10:1259427. doi: 10.3389/fmed.2023.1259427. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37680620 Free PMC article. Review.
-
Diversity, Dynamics and Therapeutic Application of Clostridioides difficile Bacteriophages.Viruses. 2022 Dec 12;14(12):2772. doi: 10.3390/v14122772. Viruses. 2022. PMID: 36560776 Free PMC article. Review.
-
Impact of Phage CDHS-1 on the Transcription, Physiology and Pathogenicity of a Clostridioides difficile Ribotype 027 Strain, R20291.Viruses. 2021 Nov 11;13(11):2262. doi: 10.3390/v13112262. Viruses. 2021. PMID: 34835068 Free PMC article.
-
Nonmammalian models to study Clostridioides difficile infection; a systematic review.Anaerobe. 2023 Feb;79:102694. doi: 10.1016/j.anaerobe.2023.102694. Epub 2023 Jan 7. Anaerobe. 2023. PMID: 36626950 Free PMC article.
-
Preclinical data and safety assessment of phage therapy in humans.Curr Opin Biotechnol. 2021 Apr;68:310-317. doi: 10.1016/j.copbio.2021.03.002. Epub 2021 Apr 13. Curr Opin Biotechnol. 2021. PMID: 33862490 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources